Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06504927
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Biomarker Discovery in Lung Cancer - Malaysia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Biomarker Discovery in Lung Cancer - Malaysia
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to
1 Identify biomarkers and signatures to differentiate between high-risk and lung cancer patients
2 Discover blood-based biomarkers that can be used as an adjunct test to imaging diagnosis to improve patient follow-up
1 Identify biomarkers and signatures to differentiate between high-risk and lung cancer patients
2 Discover blood-based biomarkers that can be used as an adjunct test to imaging diagnosis to improve patient follow-up
Detailed Description:
With existing evidence showing the utility of using liquid biopsy for early cancer detection the investigators hypothesized that cell-free DNA andor RNA expression changes during disease progression and biomarker signature can be derived from the changes in expression levels The investigators aim to discover and validate RNA and methylated cell-free DNA cancer biomarkers that can discriminate between high-risk and lung cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None